Umbilical cord blood is a rich source of hematopoietic stem cells that has been used for transplantation for over 30 years, especially when there is no compatible hematopoietic stem cell donor available. Its use has decreased more recently, since the development of methods to improve haploidentical transplants has allowed the use of mobilized peripheral blood as a source of hematopoietic stem cells. Public cord blood banks collect, process and store cord blood samples from voluntary donations. In addition, many public banks are involved in research to enhance hematopoietic stem cell therapies and develop new treatments for haematological and genetic diseases. The COVID-19 pandemic, which emerged in 2019, has had a profound and wide-ranging impact on human health and treatment. The area of hematopoietic stem cell transplantation was deeply affected by reductions in bone marrow, peripheral blood and cord blood donations; logistical challenges; exposure of healthcare workers and other challenges. The present study reviews the impact of the COVID-19 pandemic on cord blood banking and transportation around the world with a special focus on Brazil.

脐带血是造血干细胞的丰富来源，用于移植已有 30 多年的历史，特别是在没有相容的造血干细胞供体的情况下。最近它的使用已经减少，因为改进单倍体移植的方法的开发允许使用动员的外周血作为造血干细胞的来源。公共脐带血库收集、处理和储存自愿捐赠的脐带血样本。此外，许多公共银行还参与增强造血干细胞疗法的研究，并开发血液和遗传疾病的新疗法。2019年出现的COVID-19大流行对人类健康和治疗产生了深远而广泛的影响。造血干细胞移植领域深受骨髓、外周血、脐带血捐献减少的影响；后勤挑战；医护人员的暴露和其他挑战。本研究回顾了 COVID-19 大流行对世界各地脐带血库和运输的影响，特别关注巴西。